WO2004092207A3 - Respiratory syncytial virus (rsv) peptides - Google Patents
Respiratory syncytial virus (rsv) peptides Download PDFInfo
- Publication number
- WO2004092207A3 WO2004092207A3 PCT/EP2004/004061 EP2004004061W WO2004092207A3 WO 2004092207 A3 WO2004092207 A3 WO 2004092207A3 EP 2004004061 W EP2004004061 W EP 2004004061W WO 2004092207 A3 WO2004092207 A3 WO 2004092207A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptides
- rsv
- respiratory syncytial
- syncytial virus
- vaccines
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 241000725643 Respiratory syncytial virus Species 0.000 title 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03447095.5 | 2003-04-16 | ||
EP03447095 | 2003-04-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004092207A2 WO2004092207A2 (en) | 2004-10-28 |
WO2004092207A3 true WO2004092207A3 (en) | 2005-04-07 |
Family
ID=33186034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/004061 WO2004092207A2 (en) | 2003-04-16 | 2004-04-16 | Respiratory syncytial virus (rsv) peptides |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2004092207A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1840133A1 (en) * | 2006-03-29 | 2007-10-03 | Global Biotech Development Corp. Ltd. | New immunomodulating oligopeptides |
FR2903305B1 (en) * | 2006-07-07 | 2012-06-01 | Soc Extraction Principes Actif | USE OF PLANT EXTRACTS AS SLIMMING ACTIVE INGREDIENTS |
JP2010534057A (en) | 2007-03-06 | 2010-11-04 | シムフォゲン・アクティーゼルスカブ | Recombinant antibody for treating respiratory syncytial virus infection |
GB0823366D0 (en) | 2008-12-22 | 2009-01-28 | Uni I Oslo | Synthesis |
MX2013002303A (en) * | 2010-09-07 | 2013-10-28 | Oncotherapy Science Inc | Ttll4 peptides and vaccines containing the same. |
ES2657470T3 (en) | 2012-03-20 | 2018-03-05 | Humabs Biomed S.A. | Antibodies that neutralize RSV, MPV and PVM and their uses |
KR102119197B1 (en) * | 2018-04-23 | 2020-06-05 | 주식회사 엘베이스 | Composition for autophagy inhibiting in cell, And pharmaceutical composition for preventing or treating tumor disease, or inhibiting anti-cancer agents resistance containing the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994020127A1 (en) * | 1993-03-05 | 1994-09-15 | Cytel Corporation | Hla-a2.1 binding peptides and their uses |
WO1999014334A1 (en) * | 1997-09-19 | 1999-03-25 | American Cyanamid Company | Peptides derived from the attachment (g) protein of respiratory syncytial virus |
-
2004
- 2004-04-16 WO PCT/EP2004/004061 patent/WO2004092207A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994020127A1 (en) * | 1993-03-05 | 1994-09-15 | Cytel Corporation | Hla-a2.1 binding peptides and their uses |
WO1999014334A1 (en) * | 1997-09-19 | 1999-03-25 | American Cyanamid Company | Peptides derived from the attachment (g) protein of respiratory syncytial virus |
Non-Patent Citations (5)
Title |
---|
DE GROOT, A.S. ET AL.: "Immuno-informatics: Mining genomes for vaccine components", IMMUNOLOGY AND CELL BIOLOGY, vol. 80, no. 3, June 2002 (2002-06-01), pages 255 - 269, XP002254696 * |
HSU, S.-C. ET AL.: "Reduction of Respiratory Syncytial Virus Titer in the Lungs of Mice after Intranasal Immunization with a Chimeric Peptide Consisting of a Single CTL Epitope Linked to a Fusion Peptide", VIROLOGY, vol. 240, no. 2, 20 January 1998 (1998-01-20), pages 376 - 381, XP002254698 * |
HUSSELL, T. ET AL.: "CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 27, no. 12, December 1997 (1997-12-01), pages 3341 - 3349, XP008035228 * |
KULKARNI, A.B. ET AL.: "Cytotoxic T Cells Specific for a Single Peptide on the M2 Protein of Respiratory Syncytial Virus Are the Sole Mediators of Resistence Induced by Immunization with M2 Encoded by a Recombinant Vaccinia Virus", JOURNAL OF VIROLOGY, vol. 69, no. 2, February 1995 (1995-02-01), pages 1261 - 1264, XP002254697 * |
MELERO, J.A. ET AL.: "Antigenic structure, evolution and immunobiology of the human respiratory syncytial virus attachment (G) protein", JOURNAL OF GENERAL VIROLOGY, vol. 78, no. 10, October 1997 (1997-10-01), pages 2411 - 2418, XP001018065 * |
Also Published As
Publication number | Publication date |
---|---|
WO2004092207A2 (en) | 2004-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004075829A3 (en) | Adjuvanted influenza vaccine | |
WO2006034292A3 (en) | Antibodies against and methods for producing vaccines for respiratory syncytial virus | |
WO2004014418A3 (en) | Neisserial vaccine compositions comprising a combination of antigens | |
WO2008061243A3 (en) | Respiratory syncytial virus-virus like particle (vlps) | |
EP4219566A3 (en) | Recombinant rsv antigens | |
WO2006038908A3 (en) | Ancestral and cot viral sequences, proteins and immunogenic compositions | |
WO2006113214A3 (en) | Vaccine against pandemic strains of influenza viruses | |
WO2006068663A3 (en) | Vaccine compositions for treating coronavirus infection | |
WO2005089164A3 (en) | Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions | |
WO2007008918A3 (en) | Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof | |
PT1409692E (en) | Novel peptides of the respiratory syncytial virus (rsv) g protein and their use in a vaccine | |
WO2004080403A3 (en) | Influenza virus vaccine | |
WO2006115843A3 (en) | Nipah virus vaccines | |
WO2010039224A3 (en) | Respiratory syncytial virus (rsv) sequences for protein expression and vaccines | |
IL189313A0 (en) | Virus-like particles as vaccines for paramyxovirus | |
WO2006020773A3 (en) | Methods for preparing freeze-dried platelets, compositions comprising freeze-dried platelets, and methods of use | |
WO2009105152A3 (en) | Virus-like particles as vaccines for paramyxovirus | |
WO2002087494A3 (en) | Novel vaccine | |
WO2005028496A3 (en) | Vaccine for treatment and prevention of herpes simplex virus infection | |
WO2005007673A3 (en) | Immunogenic peptides | |
WO2006007555A3 (en) | Rotavirus antigens | |
WO2008024919A8 (en) | Interferon antagonists, antibodies thereto, and associated methods of use | |
WO2005058349A3 (en) | Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases | |
WO2002077012A3 (en) | Human papilloma virus immunoreative peptides | |
WO2004092207A3 (en) | Respiratory syncytial virus (rsv) peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |